Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl

Clinical Therapeutics

Volumn 39, Issue 11, 2017, Pages 2158-2168

  Anthony, Lowell ^a   Ervin, Claire ^b   Lapuerta, Pablo ^c   Kulke, Matthew H ^d   Kunz, Pamela ^e   Bergsland, Emily ^f   Hörsch, Dieter ^g   Metz, David C ^h   Pasieka, Janice ⁱ   Pavlakis, Nick ^j   Pavel, Marianne ^k   Caplin, Martyn ^l   Öberg, Kjell ^m   Ramage, John ⁿ   Evans, Emily ^b   Yang, Qi Melissa ^c   Jackson, Shanna ^c   Arnold, Karie ^c   Law, Linda ^c,o   DiBenedetti, Dana B ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ZENTRALKLINIK BAD BERKA   (Germany)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ TOM BAKER CANCER CENTRE   (Canada)

^j ROYAL NORTH SHORE HOSPITAL   (Australia)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l ROYAL FREE HOSPITAL   (United Kingdom)

^m UPPSALA UNIVERSITY   (Sweden)

ⁿ BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^o BioHealthConsult   (United States)

more..

Author keywords

bowel movement; carcinoid syndrome; diarrhea; exit interviews; patient interviews; telotristat ethyl

Indexed keywords

PLACEBO; TELOTRISTAT ETHYL; PHENYLALANINE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CANCER PATIENT; CARCINOID SYNDROME; CLINICAL ARTICLE; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG SCREENING; FEMALE; HUMAN; MALE; MIDDLE AGED; PATIENT-REPORTED OUTCOME; PERSONAL EXPERIENCE; PHYSICAL ACTIVITY; QUALITY OF LIFE; SOCIAL BEHAVIOR; TELEPHONE INTERVIEW; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; PHENYLALANINE; PYRIMIDINES; TREATMENT OUTCOME;

EID: 85032195514     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.09.013     Document Type: Article

References (23)

1. Turaga, K.K., Kvols, L.K., Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 61 (2011), 113–132.
2. Yao, J.C., Hassan, M., Phan, A., et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 (2008), 3063–3072.
3. Kulke, M.H., Mayer, R.J., Carcinoid tumors. N Engl J Med 340:11 (1999), 858–868.
4. Vinik, A.I., Woltering, E.A., O'Dorisio, T.M., Go, V.L.W., Carcinoid tumors and the carcinoid syndrome. In: Neuroendocrine tumors; a comprehensive guide to diagnosis and management, 3rd ed., 2006, Inter Science Institute, Inglewood, CA.
5. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: SEER 17 Regs Nov 2006 sub (1973–2004). 2007, National Cancer Institute, Bethesda, MD.
6. Modlin, I.M., Kidd, M., Latich, I., et al. Current status of gastrointestinal carcinoids. Gastroenterology 128 (2005), 1717–1751.
7. Horton, K.M., Kamel, I., Hofmann, L., Fishman, E.K., Carcinoid tumors of the small bowel: a multi-technique imaging approach. Am J Roentgenol 182 (2004), 559–567.
8. Vinik A., Feliberti E., Perry R.R. Carcinoid tumors, Updated August 01, 2014. http://www.ncbi.nlm.nih.gov/books/NBK279162/?report=printable. Accessed February 26, 2016.
9. Khan, A.N. Gastrointestinal carcinoid imaging, February 16, 2007. E-Medicine. www.emedicine.com/RADIO/topic126.htm. Accessed February 28, 2008.
10. Mayo Clinic. Carcinoid syndrome, 2015 http://www.mayoclinic.org/diseasesconditions/carcinoid-syndrome/basics/definition/con-20027127 Accessed November 12, 2015.
11. Robertson, R.G., Geiger, W.J., Davis, N.B., Carcinoid tumors. Am Fam Physician 74 (2006), 429–434.
12. Creutzfeldt, W., Stöckmann, F., Carcinoids and carcinoid syndrome. Am J Med 82 (1987), 4–16.
13. Caplin, M.E., Buscombe, J.R., Hilson, A.J., et al. Carcinoid tumour. Lancet 352 (1998), 799–805.
14. Beaumont, J.L., Cella, D., Phan, A.T., et al. Comparison of health-related quality of life in subjects with neuroendocrine tumors with quality of life in the general US population. Pancreas 41 (2012), 461–466.
15. Zuetenhorst, J.M., Taal, B.G., Metastatic carcinoid tumors: a clinical review. Oncologist 10 (2005), 123–131.
16. Boudreaux, J.P., Klimstra, D.S., Hassan, M.M., et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well differentiated neuroendocrine tumors of the jejunum, ileum, appendix and cecum. Pancreas 39 (2010), 753–766.
17. Kulke, M.H., Hörsch, D., Caplin, M.E., et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol 35 (2017), 14–23.
18. Gelhorn, H.L., Kulke, M.H., O'Dorisio, T., et al. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a quantitative interview approach. Clin Ther 38 (2016), 759–768.
19. Dimitriadis, G.K., Welchert, M.O., Randeva, H.S., et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 23 (2016), R423–R436.
20. Yadegarfar, G., Friend, L., Jones, L., et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer 108 (2013), 301–310.
21. King, M.T., The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5 (1996), 555–567.
22. O'Cathain, A., Thomas, K.J., Drabble, S.J., Rudolph, A., Hewison, J., What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open, 3, 2013, e002889.
23. Hassett, A.L., Maclean, R., Peterson, C., Stuart, M.R., Buyske, S., Park, N., et al. The observational evaluation of subjective well-being in patients with rheumatoid arthritis. Applied Psychology: Health and Well-Being 1 (2009), 46–61.